Clinical Trial - Nivolumab Plus Ipilimumab – Thyroid Cancer

The Dana-Farber Cancer Institute is running a clinical trial to evaluate the effectiveness (how well the drug/s work) of nivolumab combined with ipilimumab, two types of immunotherapy. Both the two drugs have been approved by the US Food and Drug Administration (FDA) for the treatment of several cancers. The combination has been approved by FDA as treatment for metastatic melanoma. Yet the use of nivolumab as well as ipilimumab alone or in combination for the treatment of patients with thyroid cancer is not approved.

Drugs are Nivolumab & Ipilimumab.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer
Actual Study Start Date : September 20, 2017
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2025

For enrollment please visit www.clinicaltrials.gov.

Contacts:

Patricia McHugh, BSN  617-632-3090 patricia_mchugh@dfci.harvard.edu

Michelle Flynn, BSN  617-632-3090  mflynn13@partners.org

Reference Code: NCT03246958

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
+ Ask Questions